All In Biotech

Drug Trial Radar · NCT05685615

PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

A Multicenter, Open-label, Randomized, Active-controlled, Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Intravenous BV100 Combined with Polymyxin B Versus Best Available Therapy in Adult Patients with Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to Be Due to Carbapenem-resistant Acinetobacter Baumannii

Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Apr 20, 2023

Primary completion

Nov 1, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
BioVersys AGIndustry
Sponsor type
Industry
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB

Conditions

  • Ventilator Associated Pneumonia

Interventions

  • BV100 plus Polymyxin BDrug

    Rifabutin for Infusion plus Polymyxin B for Injection

  • BATDrug

    The best avaialble antibiotic therapy to treat CRAB

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the pharmacokinetic (PK) properties of BV100 co administered with Polymyxin B during 7 to 14 days of treatment in patients with ventilator associated bacterial pneumonia (VABP)Time frame: 14 days
  2. To investigate the pharmacokinetic properties of BV100 co administered with Polymyxin B during 7 to 14 days of treatment in patients with ventilator associated bacterial pneumonia (VABP)Time frame: 14 days

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Academician Vakhtang Bochorishvili Clinic

    Tbilisi, Georgia

  • Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • First University Clinic of Tbilisi State Medical University

    Tbilisi, Georgia

  • Gudushauri National Medical Center

    Tbilisi, Georgia

  • Malkhaz Katsiashvili Multiprofile Emergency Medicine Center

    Tbilisi, Georgia

  • Number 5 Clinical Hospital

    Tbilisi, Georgia

  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic

    Tbilisi, Georgia

  • General Hospital of Athens "Evangelismos"

    Athens, Greece

  • University General Hospital "Attikon"

    Athens, Greece

  • General University Hospital of Heraklion

    Heraklion, Greece

  • General Hospital of Larissa

    Larissa, Greece

  • University General Hospital of Larissa

    Larissa, Greece

  • General Hospital of Thessaloniki "Ippokratio"

    Thessaloniki, Greece

  • University of Debrecen Clinical Center

    Debrecen, Hungary

  • University Educational Hospital

    Miskolc, Hungary

  • Fejer County St. Gyorgy University Teaching Hospital

    Székesfehérvár, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.